You are not logged in.

The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies

West, Christina E., Renz, Harald, Jenmalm, Maria C., Kozyrski, Anita L., Allen, Katrina J., Vuillermin, Peter and Prescott, Susan L. 2015, The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies, Journal of allergy and clinical immunology, vol. 135, no. 1, pp. 3-13, doi: 10.1016/j.jaci.2014.11.012.

Attached Files
Name Description MIMEType Size Downloads

Title The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies
Author(s) West, Christina E.
Renz, Harald
Jenmalm, Maria C.
Kozyrski, Anita L.
Allen, Katrina J.
Vuillermin, Peter
Prescott, Susan L.
Contributor(s) Leung, Donald Y. M.
Ledford, Dennis K
Journal name Journal of allergy and clinical immunology
Volume number 135
Issue number 1
Start page 3
End page 13
Total pages 11
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2015-01-31
ISSN 1097-6825
Keyword(s) fecal microbiota transplantation
gut microbiome
iflammation
noncommunicable diseases
prebiotics
probiotics
short-chain fatty acids
Summary Rapid environmental transition and modern lifestyles are likely driving changes in the biodiversity of the human gut microbiota. With clear effects on physiologic, immunologic, and metabolic processes in human health, aberrations in the gut microbiome and intestinal homeostasis have the capacity for multisystem effects. Changes in microbial composition are implicated in the increasing propensity for a broad range of inflammatory diseases, such as allergic disease, asthma, inflammatory bowel disease (IBD), obesity, and associated noncommunicable diseases (NCDs). There are also suggestive implications for neurodevelopment and mental health. These diverse multisystem influences have sparked interest in strategies that might favorably modulate the gut microbiota to reduce the risk of many NCDs. For example, specific prebiotics promote favorable intestinal colonization, and their fermented products have anti-inflammatory properties. Specific probiotics also have immunomodulatory and metabolic effects. However, when evaluated in clinical trials, the effects are variable, preliminary, or limited in magnitude. Fecal microbiota transplantation is another emerging therapy that regulates inflammation in experimental models. In human subjects it has been successfully used in cases of Clostridium difficile infection and IBD, although controlled trials are lacking for IBD. Here we discuss relationships between gut colonization and inflammatory NCDs and gut microbiota modulation strategies for their treatment and prevention. (J Allergy Clin Immunol 2015;135:3-13.)
Language eng
DOI 10.1016/j.jaci.2014.11.012
Field of Research 1107 Immunology
111799 Public Health and Health Services not elsewhere classified
Socio Economic Objective 920499 Public Health (excl. Specific Population Health) not elsewhere classified
HERDC Research category C1.1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2014 American Academy of Allergy, Asthma & Immunology
Persistent URL http://hdl.handle.net/10536/DRO/DU:30084653

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 69 times in TR Web of Science
Scopus Citation Count Cited 76 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 98 Abstract Views, 9 File Downloads  -  Detailed Statistics
Created: Mon, 04 Jul 2016, 15:05:22 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.